Urovant Sciences Competitors and Similar CompaniesClear all

Urovant Sciences's competitors and similar companies include Novartis, Astellas Pharma and Kymera Therapeutics.

	Urovant Sciences Urovant Sciences is a biopharmaceutical company focused on developing novel therapies for urologic conditions.	Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products.	Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions.	Kymera Therapeutics Kymera Therapeutics is a biotechnology company aimed to create medicines for patients with previously untreatable diseases.
Founding Date	Founding Date 2016	Founding Date 1996	Founding Date 1923	Founding Date 2017
Type	Type Subsidiary	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech pharma therapy	Tags Healthcare biotech clinical research drug development oncology pharma	Tags Healthcare diabetes drug development oncology pharma	Tags Healthcare biotech drug development therapy
Locations	Locations Irvine, US HQ Basel, CH	Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more	Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more	Locations Watertown, US HQ Cambridge, US
Employees	Employees 3950% increase	Employees 75,883	Employees 14,754	Employees 207
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 20.8 b	Valuation ($) 3.1 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $56.7b (FY, 2025)	Revenue (est.) ¥2.1t (FY, 2026)	Revenue (est.) $39.2m (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods $8.4b (FY, 2025)	Cost of goods ¥213.8b (FY, 2026)	Cost of goods $39.2m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit $49.8b (FY, 2025)	Gross profit ¥2t (FY, 2026)	Gross profit N/A
Net income	Net income ($146.7m) (FY, 2020)	Net income $14b (FY, 2025)	Net income ¥291.6b (FY, 2026)	Net income ($311.4m) (FY, 2025)
Operating ⚠
Phase III Trials Products (Oncology)	Phase III Trials Products (Oncology) N/A	Phase III Trials Products (Oncology) 27 (FY, 2021)	Phase III Trials Products (Oncology) 4 (Oct, 2020)	Phase III Trials Products (Oncology) N/A
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 6.5m	Total funding raised N/A	Total funding raised $ 197m